Janux Therapeutics (JANX) Non-Current Assets (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Non-Current Assets data on file, last reported at $26.2 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 4.58% year-over-year to $26.2 million in Q1 2026; TTM through Mar 2026 was $105.2 million, a 7.28% decrease from a year earlier, with the FY2025 full-year figure at $25.7 million, down 7.8% from the prior year.
• Non-Current Assets for Q1 2026 stood at $26.2 million, up from $25.7 million in the prior quarter.
• Over the last five years, Non-Current Assets for JANX reached as high as $32.2 million in Q2 2023 and fell as low as $3.9 million in Q1 2022.
• Historically, Non-Current Assets has averaged $27.6 million across 5 years, with a median of $28.7 million in 2024.
• Across the five-year window, Non-Current Assets soared 12597.67% in 2022 and retreated 10.64% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $31.6 million in 2022, then fell by 1.28% to $31.2 million in 2023, then decreased by 10.64% to $27.8 million in 2024, then fell by 7.8% to $25.7 million in 2025, then advanced by 1.94% to $26.2 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $26.2 million in Q1 2026, $25.7 million in Q4 2025, and $26.7 million in Q3 2025.